BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global Cardiac Catheters industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The report further provides details about each segments and regions covered in the global Diagnostic Biomarkers market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

Tvardi Therapeutics, Inc. (“Tvardi”), today announced its collaborators will present preclinical data demonstrating TTI-101 overcomes palbociclib resistance in metastatic breast cancer murine models at the upcoming 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, LA, from April 8th – 13th, 2022.

Upon completion of the Additional ADSL Purchase, Britannia will own a 70% interest in ADSL, Britannia’s largest operating subsidiary.

CytoImmune Therapeutics announced that Christina Coughlin, M.D., Ph.D., chief executive officer, will participate in the following April investor conferences.

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022.

GENFIT announced annual financial results for the year ended December 31, 2021.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the first quarter of 2022 to be in the range of $990 million to $1,000 million, or growth of 164% to 166% from the first quarter 2021 revenue of $375.3 million.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2022 results before the market opens on Tuesday, May 3, 2022, to be followed by a conference call at 8:30 a.m. (Eastern Time).

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, announced that management will participate in the following investor conference.